IL6 and congenital rubella syndrome: Since the pathophysiology of the CRS and CRES incited by blinatumomab is similar to CARTox, and IL-6 blockade is equally effective for CRS, it is possible that macrophage-produced IL-1 plays a major role in the toxicities [42].